Five randomized trials have been conducted to prove that shorter duration of trastuzumab treatment (9 weeks or 6 months) can replace the standard duration (1 year). The results of PERSEPHONE, the most recent trial, suggest that the efficacy of a 6-month treatment is non-inferior to that of 1 year, although not for all patients. We discuss these results in the context of current treatment standards.

中文翻译：

---

PERSEPHONE-对2019年临床实践的影响。

已经进行了五项随机试验，以证明曲妥珠单抗治疗的持续时间较短（9周或6个月）可以代替标准持续时间（1年）。最近的一项试验PERSEPHONE的结果表明，尽管并非对所有患者而言，6个月治疗的疗效均不低于1年。我们在当前治疗标准的背景下讨论这些结果。